XML 38 R17.htm IDEA: XBRL DOCUMENT
v3.20.4

Marketable Securities | 12 Months Ended
--- | ---
Dec. 31, 2020
Debt Securities, Available-for-sale [Abstract] |
Marketable Securities | Marketable SecuritiesRambus invests its excess cash and cash equivalents primarily in U.S. government-sponsored obligations, commercial paper, corporate notes and bonds, money market funds and municipal notes and bonds that mature within three years. All cash equivalents and marketable securities are classified as available-for-sale. Total cash, cash equivalents and marketable securities are summarized as follows:
|  | As of December 31, 2020
(Dollars in thousands) |  | Fair Value |  | Amortized Cost |  | Gross Unrealized Gains |  | Gross Unrealized Losses |  | Weighted Rate of Return
Money market funds |  | $ | 32,815 |  |  | $ | 32,815 |  |  | $ | — |  |  | $ | — |  |  | 0.01 | %
U.S. Government bonds and notes |  | 169,880 |  |  | 169,920 |  |  | 3 |  |  | (43) |  |  | 0.12 | %
Corporate notes, bonds and commercial paper |  | 238,491 |  |  | 238,509 |  |  | 61 |  |  | (79) |  |  | 0.21 | %
Total cash equivalents and marketable securities |  | 441,186 |  |  | 441,244 |  |  | 64 |  |  | (122) |  |  |
Cash |  | 61,463 |  |  | 61,463 |  |  | — |  |  | — |  |  |
Total cash, cash equivalents and marketable securities |  | $ | 502,649 |  |  | $ | 502,707 |  |  | $ | 64 |  |  | $ | (122) |  |  |
|  | As of December 31, 2019
(Dollars in thousands) |  | Fair Value |  | Amortized Cost |  | Gross Unrealized Gains |  | Gross Unrealized Losses |  | Weighted Rate of Return
Money market funds |  | $ | 10,065 |  |  | $ | 10,065 |  |  | $ | — |  |  | $ | — |  |  | 1.48 | %
U.S. Government bonds and notes |  | 39,086 |  |  | 39,087 |  |  | — |  |  | (1) |  |  | 1.49 | %
Corporate notes, bonds and commercial paper |  | 314,391 |  |  | 314,435 |  |  | 19 |  |  | (63) |  |  | 1.81 | %
Total cash equivalents and marketable securities |  | 363,542 |  | 363,587 |  | 19 |  |  | (64) |  |  |
Cash |  | 44,122 |  |  | 44,122 |  |  | — |  |  | — |  |  |
Total cash, cash equivalents and marketable securities |  | $ | 407,664 |  |  | $ | 407,709 |  |  | $ | 19 |  |  | $ | (64) |  |  |
Available-for-sale securities are reported at fair value on the balance sheets and classified as follows:
|  | As of December 31,
(In thousands) |  | 2020 |  | 2019
Cash equivalents |  | $ | 74,683 |  |  | $ | 58,054 |
Short-term marketable securities |  | 366,503 |  |  | 305,488 |
Total cash equivalents and marketable securities |  | 441,186 |  | 363,542
Cash |  | 61,463 |  |  | 44,122 |
Total cash, cash equivalents and marketable securities |  | $ | 502,649 |  |  | $ | 407,664 |
The Company continues to invest in highly rated quality, highly liquid debt securities. The Company holds all of its marketable securities as available-for-sale, marks them to market, and regularly reviews its portfolio to ensure adherence to its investment policy and to monitor individual investments for risk analysis, proper valuation, and unrealized losses that may be other than temporary. The estimated fair value and gross unrealized losses of cash equivalents and marketable securities classified by the length of time that the securities have been in a continuous unrealized loss position at December 31, 2020 and 2019 are as follows:
|  | Fair Value |  | Gross Unrealized Loss |
(In thousands) |  | December 31, 2020 |  | December 31, 2019 |  | December 31, 2020 |  | December 31, 2019 |
Less than 12 months |  |  |  |  |  |  |  |  |
U.S. Government bonds and notes |  | $ | 72,896 |  |  | $ | 14,112 |  |  | $ | (43) |  |  | $ | (1) |  |
Corporate notes, bonds and commercial paper |  | 181,354 |  |  | 250,822 |  |  | (79) |  |  | (63) |  |
Total cash equivalents and marketable securities in a continuous unrealized loss position |  | $ | 254,250 |  |  | $ | 264,934 |  |  | $ | (122) |  |  | $ | (64) |  |
The gross unrealized loss at December 31, 2020 and 2019 was not material in relation to the Company’s total available-for-sale portfolio. The gross unrealized loss can be primarily attributed to a combination of market conditions as well as the demand for and duration of the U.S. government-sponsored obligations and corporate notes and bonds. The Company reasonably believes that there is no need to sell these investments and that it can recover the amortized cost of these investments. The Company has found no evidence of impairment due to credit losses in its portfolio. Therefore, these unrealized losses were recorded in other comprehensive income (loss). However, the Company cannot provide any assurance that its portfolio of cash, cash equivalents and marketable securities will not be impacted by adverse conditions in the financial markets, which may require the Company in the future to record an impairment charge for credit losses which could adversely impact its financial results. The contractual maturities of cash equivalents (excluding money market funds which have no maturity) and marketable securities are summarized as follows:
(In thousands) |  | December 31, 2020
Due less than one year |  | $ | 334,332 |
Due from one year through three years |  | 74,039 |
Total |  | $ | 408,371 |
Refer to Note 9, “Fair Value of Financial Instruments,” for discussion regarding the fair value of the Company’s cash equivalents and marketable securities.

X
- References No definition available. + Details
Name: | us-gaap_AvailableForSaleSecuritiesAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for cash, cash equivalents, investments in debt and equity instruments (including cost and equity investees and related income statement amounts), equity and cost method investments, investments in joint ventures and any other investment. + References No definition available. + Details
Name: | us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration